Saturday 17 October 2026
Export DWTX’s income statement to Excel — free account
Dogwood Therapeutics, Inc
DWTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 82.9% and free cash flow grew 10.3%, each against the same quarter a year earlier.
1.22
0.03
−2.40%
Follow DWTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 180.25 | 100.00 | 5.48 | 5.55 | 1.62 | 1.87 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 417.75 | 233.00 | 227.78 | 60.50 | 23.50 | 29.28 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 5 | 4 | 4 | 12 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | (2) | (2) | (10) | (16) | (12) | (5) | (12) | (34) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (2) | (2) | (10) | (16) | (12) | (5) | (12) | (34) | |||||
| Depreciation | — | — | — | 0 | 0 | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.26) | (12.80) | (52.50) | (48.00) | (27.75) | (7.00) | (12.52) | (7.13) | |||||
| Cash flow | — | — | (0.15) | (10.82) | (19.76) | (47.09) | (25.90) | (6.49) | (8.55) | (3.14) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (0.15) | (10.82) | (19.76) | (47.09) | (25.90) | (6.49) | (8.55) | (3.14) | |||||
| Book value | — | — | (1.83) | (25.96) | 151.91 | 43.52 | 16.55 | 5.07 | 62.53 | 15.05 | |||||
| Shares, m | — | — | 8 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (2) | (4) | (16) | (11) | (5) | (9) | (16) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | (1) | (2) | (4) | (16) | (11) | (5) | (9) | (16) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (1) | (1) | 30 | 15 | 7 | 4 | 13 | 5 | ||||
| Total debt | — | — | — | 4 | — | — | — | — | 15 | — | |||||
| Net debt | — | — | 0 | 3 | (30) | (14) | (7) | (3) | 1 | (7) | |||||
| Shareholders’ equity | — | — | (15) | (5) | 30 | 15 | 7 | 4 | 64 | 75 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (6,414.57) | (1,295.76) | (65.10) | (67.56) | (101.45) | (84.50) | (26.13) | (38.50) | ||||
| ROIC | — | — | 0.00 | 0.00 | (4,297.85) | (1,983.28) | (2,604.76) | (694.76) | (11.79) | (25.57) | |||||
| ROE | — | — | 12.90 | 24.54 | (83.03) | (71.83) | (112.22) | (95.14) | 407.25 | (109.66) | |||||
Negative figures in brackets.
Charts ten years each
Dogwood Therapeutics, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SER Serina Therapeutics, Inc. | $45.5M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $44.8M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $44.5M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $43.2M | — (loss-making) | — (loss-making) | −66.34% (below 0%: shrinking) | n/m | +148.35% (above 0%: growing) | 62.25% | (263.47%) | Compare |
| DWTX Dogwood Therapeutics, Inc | $42.5M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| VERU Veru Inc. | $41.6M | — (loss-making) | — (loss-making) | +287.06% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 34.92% | 0.00% | Compare |
| TIL Instil Bio, Inc. | $41.6M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $41.0M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $42.5M | — | — | +287.06% | — | +13.24% | 34.92% | 0.00% |
Dogwood Therapeutics, Inc (DWTX) key facts
- Dogwood Therapeutics, Inc (DWTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, DWTX traded at $1.22, a market capitalization of $42.5 million.
- Return on equity was −109.7% and debt-to-equity 0.00.